BRPI1011505A2 - formas de pró-drogas de inibidores de quinase e sua aplicação em terapia - Google Patents
formas de pró-drogas de inibidores de quinase e sua aplicação em terapiaInfo
- Publication number
- BRPI1011505A2 BRPI1011505A2 BRPI1011505A BRPI1011505A BRPI1011505A2 BR PI1011505 A2 BRPI1011505 A2 BR PI1011505A2 BR PI1011505 A BRPI1011505 A BR PI1011505A BR PI1011505 A BRPI1011505 A BR PI1011505A BR PI1011505 A2 BRPI1011505 A2 BR PI1011505A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapy
- application
- kinase inhibitor
- prodrug forms
- inhibitor prodrug
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ57549009 | 2009-03-11 | ||
| NZ57945809 | 2009-09-02 | ||
| NZ58117009 | 2009-11-12 | ||
| PCT/NZ2010/000040 WO2010104406A1 (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011505A2 true BRPI1011505A2 (pt) | 2016-03-22 |
Family
ID=42728538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011505A BRPI1011505A2 (pt) | 2009-03-11 | 2010-03-11 | formas de pró-drogas de inibidores de quinase e sua aplicação em terapia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9073916B2 (pt) |
| EP (2) | EP3031807A1 (pt) |
| JP (1) | JP5793428B2 (pt) |
| KR (1) | KR20110130468A (pt) |
| CN (2) | CN102348708A (pt) |
| AU (1) | AU2010221818A1 (pt) |
| BR (1) | BRPI1011505A2 (pt) |
| CA (1) | CA2754808C (pt) |
| IL (1) | IL214626A0 (pt) |
| MX (1) | MX2011009034A (pt) |
| NZ (2) | NZ595206A (pt) |
| RU (1) | RU2011141121A (pt) |
| WO (1) | WO2010104406A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120022370A (zh) | 2005-02-03 | 2025-05-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| US20070104721A1 (en) | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2431355T3 (es) | 2008-06-17 | 2013-11-26 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| DK2326329T3 (en) | 2008-08-04 | 2017-02-20 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| MX2011009034A (es) | 2009-03-11 | 2011-09-22 | Auckland Uniservices Ltd | Formas de profarmaco de inhibidores de cinasa y su uso en la terapia. |
| EP4218760A3 (en) | 2009-04-06 | 2023-08-16 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
| RU2568639C2 (ru) * | 2009-09-02 | 2015-11-20 | Окленд Юнисервисиз Лимитед | Ингибиторы киназы, их пролекарственные формы и их применение в терапии |
| CN102558185B (zh) * | 2010-12-09 | 2016-02-10 | 中国科学院上海药物研究所 | 吡啶并吡咯三嗪化合物、其制备方法和用途 |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| EP2833886B1 (en) * | 2012-04-04 | 2020-08-12 | HangzhouDeRenYuCheng Biotechnology Ltd. | Substituted quinolines as bruton's tyrosine kinase inhibitors |
| CN105796562A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN105796569A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN103664797A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103655576A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103724349A (zh) * | 2012-10-11 | 2014-04-16 | 韩冰 | 一类治疗脑性瘫痪的化合物及其用途 |
| CN102952095A (zh) * | 2012-10-19 | 2013-03-06 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法 |
| CN103784456A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103787986A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103804304A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
| SG11201506972PA (en) * | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| EP2986294A4 (en) | 2013-04-17 | 2016-11-16 | Biopharma Works | PROCESS FOR PAIN TREATMENT |
| US9487531B2 (en) | 2013-04-17 | 2016-11-08 | BioPharma Works LLC | Compounds for treatment of pain |
| CN105705494B (zh) * | 2013-07-18 | 2017-12-15 | 锦州奥鸿药业有限责任公司 | 喹唑啉衍生物及其药物组合物，以及作为药物的用途 |
| US10507210B2 (en) | 2014-12-03 | 2019-12-17 | Auckland Uniservices Limited | Kinase inhibitor prodrug for the treatment of cancer |
| WO2017004005A1 (en) * | 2015-06-29 | 2017-01-05 | Ontogenesis, Llc | N-acylalkyl prodrugs of multi-tyrosine kinase inhibitors and methods of use |
| KR102583737B1 (ko) * | 2017-03-03 | 2023-09-26 | 오클랜드 유니서비시즈 리미티드 | Fgfr 키나제 저해제 및 약학적 용도 |
| CN107569491A (zh) * | 2017-08-30 | 2018-01-12 | 杭州科兴生物化工有限公司 | 一种星孢菌素类化合物的应用 |
| CN111527103A (zh) | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| JP7483620B2 (ja) * | 2018-02-28 | 2024-05-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 |
| WO2021003339A1 (en) * | 2019-07-03 | 2021-01-07 | The Regents Of The University Of Colorado, A Body Corporate | Amp-activated protein kinase inhibitors and methods of making and using the same |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| WO2022006412A2 (en) | 2020-07-02 | 2022-01-06 | The Regents Of The University Of Colorado, A Body Corporate | Conjugates of ampk inhibitors and protac degraders and related uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2196165T3 (es) | 1995-08-18 | 2003-12-16 | Auckland Uniservices Ltd | Terapia de citoxina activada por radiacion. |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| AU2004229163A1 (en) | 2003-04-16 | 2004-10-28 | F. Hoffmann-La Roche Ag | (6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| KR100885835B1 (ko) | 2004-05-06 | 2009-02-26 | 워너-램버트 캄파니 엘엘씨 | 4-페닐아미노-퀴나졸린-6-일-아미드 |
| GB0421294D0 (en) | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
| EP1948180B1 (en) * | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| WO2008039087A2 (en) | 2006-09-29 | 2008-04-03 | Auckland Uniservices Limited | Indoline derivatives and uses thereof |
| WO2008151253A1 (en) | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| MX2011009034A (es) | 2009-03-11 | 2011-09-22 | Auckland Uniservices Ltd | Formas de profarmaco de inhibidores de cinasa y su uso en la terapia. |
-
2010
- 2010-03-11 MX MX2011009034A patent/MX2011009034A/es unknown
- 2010-03-11 JP JP2011553972A patent/JP5793428B2/ja active Active
- 2010-03-11 KR KR1020117023889A patent/KR20110130468A/ko not_active Ceased
- 2010-03-11 NZ NZ595206A patent/NZ595206A/en not_active IP Right Cessation
- 2010-03-11 BR BRPI1011505A patent/BRPI1011505A2/pt not_active IP Right Cessation
- 2010-03-11 CN CN2010800114500A patent/CN102348708A/zh active Pending
- 2010-03-11 WO PCT/NZ2010/000040 patent/WO2010104406A1/en not_active Ceased
- 2010-03-11 US US13/138,429 patent/US9073916B2/en active Active
- 2010-03-11 EP EP16150071.5A patent/EP3031807A1/en not_active Withdrawn
- 2010-03-11 RU RU2011141121/04A patent/RU2011141121A/ru not_active Application Discontinuation
- 2010-03-11 AU AU2010221818A patent/AU2010221818A1/en not_active Abandoned
- 2010-03-11 CA CA2754808A patent/CA2754808C/en active Active
- 2010-03-11 EP EP10751067.9A patent/EP2406262B1/en active Active
- 2010-03-11 CN CN201610031117.5A patent/CN105541836A/zh active Pending
- 2010-03-11 NZ NZ620000A patent/NZ620000A/en not_active IP Right Cessation
-
2011
- 2011-08-11 IL IL214626A patent/IL214626A0/en unknown
-
2015
- 2015-06-04 US US14/731,309 patent/US20160002222A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL214626A0 (en) | 2011-09-27 |
| JP5793428B2 (ja) | 2015-10-14 |
| CA2754808C (en) | 2019-01-08 |
| CA2754808A1 (en) | 2010-09-16 |
| WO2010104406A8 (en) | 2011-10-06 |
| WO2010104406A1 (en) | 2010-09-16 |
| EP2406262A4 (en) | 2012-06-20 |
| NZ595206A (en) | 2014-02-28 |
| US20120077811A1 (en) | 2012-03-29 |
| NZ620000A (en) | 2015-07-31 |
| MX2011009034A (es) | 2011-09-22 |
| JP2012520295A (ja) | 2012-09-06 |
| EP3031807A1 (en) | 2016-06-15 |
| EP2406262B1 (en) | 2016-02-17 |
| RU2011141121A (ru) | 2013-04-20 |
| EP2406262A1 (en) | 2012-01-18 |
| CN105541836A (zh) | 2016-05-04 |
| US9073916B2 (en) | 2015-07-07 |
| US20160002222A1 (en) | 2016-01-07 |
| CN102348708A (zh) | 2012-02-08 |
| KR20110130468A (ko) | 2011-12-05 |
| AU2010221818A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011505A2 (pt) | formas de pró-drogas de inibidores de quinase e sua aplicação em terapia | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| EP2344481A4 (en) | VIRUS AND FUNGI | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| CY2015013I1 (el) | Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων | |
| HRP20170936T1 (hr) | Alkilamido spojevi i njihova uporaba | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| DK3417701T3 (da) | Genmodificerede mus og indpodning | |
| BRPI0913594A2 (pt) | filtro rosqueável com rosca externas e métodos | |
| IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
| NO20082895L (no) | Hoytrykks-hoyspenningspenetratorsammensetning | |
| DK2185552T3 (da) | Dipeptoid-prodrugs og anvendelse heraf | |
| SMT201400164B (it) | Morfolino pirimidine e loro uso in terapia | |
| BRPI0817890A2 (pt) | Folha e artigo | |
| DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
| BR112012005774B8 (pt) | uso de um inibidor de quinase antiangiogênico no tratamento de câncer | |
| IL207415A0 (en) | Protein kinase inhibitors and use thereof | |
| BRPI0816789A2 (pt) | Goji e inflamação | |
| DK2358710T3 (da) | AKT- og P70-S6-kinaseinhibitorer | |
| DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
| ZA201003420B (en) | Protein kinase inhibitors and use thereof | |
| BRPI0920850A2 (pt) | novos compostos e sua utilização | |
| BRPI0807421A2 (pt) | Microrganismo recombinante | |
| BR112012004720A2 (pt) | inibidores de cinase, formas de profármaco dos mesmos e seu uso em terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |